Sepracor - Scientific Abstracts : XOPENEX(R) (levalbuterol)

AAAAI (American Academy of Allergy, Asthma & Immunology)
1. Andrews T, McGintee E, Tyler L, Mittal M, Chew A, Pawlowski N, Zorc J. Efficacy of high-dose continuous nebulized levalbuterol for pediatric status asthmaticus (Abstract). JACI 2007;(1):S244.

2. Duru EA, Parks JL, Calhoun WJ, Ameredes BT. Modulation of effects of albuterol enantiomers on IL-6 release in human airway smooth muscle cells as a function of cellstimulation (Abstract). JACI 2007;(1):S296.

3. McVicar WK, Bonasia P, Ong S. Compatability of levalbuteol inhalation solution mixed with budesonide, ipratropium bromide, cromolyn sodium or acetylcysteine sodium (Abstract). JACI 2007;(1):S1.

AAC (Aspen Allergy Conference)
4. Hanrahan JP, Wechsler ME, Israel E, Tripp K, Koester JF, Baumgartner RA. Polymorphisms at amino acid position 16 & 17 of the b2-adrenergic receptor affect airway function & exacerbations in response to regular b-agonist use. Presented as a platform presentation at the Aspen Allergy Conference, July 24 – 27, 2007 in Aspen CO [Abstract]

ATS (American Thoracic Society)
5. Agrawal DK, Cheng G, Kelbe PW. Effect of (s)-albuterol on corticosteroid-induced inhibition of CREB activation in human airway smooth muscle cells. Proceedings of the American Thoracic Society 2007;4:A188 [Abstract]

6. Delmotte PH, Sanderson MJ. A comparison of the effects of R- and S-albuterol on the contraction of smooth muscle cells of the small airways of mouse lung slices. Proceedings of the American Thoracic Society 2007;4:A661 [Abstract]

7. Dhand R, Delgado C, DeClue A, Spinka C, Reinero C. Effects of regular, inhaled racemic albuterol and its single isomers on inflammatory cells in broncho-alveolar lavage of healthy cats. Proceedings of the American Thoracic Society 2007;4:A464 [Abstract]

8. Endter S, Passante E, Tindal MH, Pankratz MR, Frankish NH, Ehrhardt C. Albuterol but not formoterol show enantiomer-dependent net absorption across human bronchial epithelial cell layers. Proceedings of the American Thoracic Society 2007;4:A751 [Abstract]

9. Georas SN, Porter M, Claus R, Williams MA. Dysregulated allergen-driven cytokine gene expression in dendritic cells from allergic subjects. Proceedings of the American Thoracic Society 2007;4:A922 [Abstract]

10. Gordon E, Jen K, Finn PW. Differential effects of (r)- and (s)-albuterol in t lymphocytes. Proceedings of the American Thoracic Society 2007;4:A315 [Abstract]

11. Gardner A, Smith B, Landry C. Effect of enantiomers of albuterol on pro-dilatory signaling in human airway smooth muscle cells. Proceedings of the American Thoracic Society 2007;4:A116 [Abstract]

12. Goncharova EA, Thambinayagam BA, Goncharov DA, Krymskaya VP, Panettieri RA. (R)-albuterol, but not (s)-albuterol, promotes protein kinase A-dependent vasodilator-stimulated phosphoprotein phosphorylation and inhibits migration of human airway smooth muscle cells. Proceedings of the American Thoracic Society 2007;4:A661 [Abstract]

13. Hanrahan JP, Wechsler ME, Israel E, Tripp K, Claus R, Baumgartner RA. Polymorphisms at amino acid positions 16 & 27 of ADRβ2: Airway function & exacerbations with regular vs PRN inhaled β2 agonist use. Proceedings of the American Thoracic Society 2007;4:A830 [Abstract]

14. Rehan VK, Kasdi A, Abed F, Sakurai R, Wang Y, Santos J, Torday JS. Effect of the β2-adrenergic agonist albuterol on parathyroid hormone-related protein signaling by pulmonary alveolar type II cells. Proceedings of the American Thoracic Society 2007;4:A887 [Abstract]

15. Schaefer K, Claus R, McVicar W, Hanrahan JP. A placebo-controlled study of the effects of levalbuterol and racemic albuterol on pulmonary function. Proceedings of the American Thoracic Society 2007;4:A692 [Abstract]

16. Waterman JT, Park JA, Crews AL, Adler KB. The (s)-enantiomer of albuterol activates expression of iNOS via activation of NF-κβ in primary cultures of normal human bronchial epithelial cells. Proceedings of the American Thoracic Society 2007;4:A178 [Abstract]

17. Williams MA, Porter M, Claus R, Georas SN. Albuterol modulates allergen-dependent myeloid dendritic cell activation. Proceedings of the American Thoracic Society 2007;4:A924 [Abstract]

COWC (Colleges of Worcester Consortium)
18. Gardner A. Understanding respiratory diseases: improving therapy. Presented as a poster at the Colleges of Worcester Consortium Research Showcase, April 11, 2007, Worcester, MA. [Abstract]

ISPOR (International Society for Pharmacoeconomics and Outcomes Research)
19. Claus R, Noe L, Pasta D, Schaefer K, Andrews W, Roach J. Pharmacoeconomic outcomes of levalbuterol and racemic albuterol in hospitalized patients requiring nebulization therapy (POLARIS). Value in Health 2007;10(3):A110 [Abstract]

20. Pasta D, Silva S, Noe L, Claus R, Schaefer K, Andrews W, Roach J. Quality-adjusted length of stay analysis of hospitalized patients with asthma or COPD treated with levalbuterol or racemic albuterol. Value in Health 2007;10(3):A111 [Abstract]

SWAF (Southwest Allergy Forum)
21. McVicar WK, Korenblat PE, Pleskow WW, Rees Wc, Parsey M, Tripp K, Baumgartner RA. Cumulative dose tolerability study of levalbuterol HFA and racemic albuterol HFA in patients with asthma (Abstract). Presented as a poster at the Southwest Allergy Fourm, January 17 - 21, 2007 in Puerta Vallarta, Mexico.

22. McVicar WK, Hamilos DL, D’Urzo AD, Marcus MG, Parsey M, Tripp K, Baumgartner RA. Long-term safety of levalbuterol administered via metered dose inhaler in patients with asthma. Presented as a poster at the Southwest Allergy Forum, January 17 – 21, 2007 in Puerta Vallarta, Mexico. [Abstract]

WSAAI (Western Society of Allergy, Asthma & Immunology)
23. Pearlman DS, Rees W, Huang H, Schaefer K, Andrews W. An evaluation of levalbuterol HFA in the prevention of exercise-induced bronchospasm (Abstract). Presented as a poster at Western Society of Allergy, Asthma, & Immunology 2007 in Maui, Hawaii.

WSPR (Western Society for Pediatric Research)
24. Rehan VK, Kasdi A, Abed F, Sakurai R, Wang Y, Santos J, Torday JS. Effect of the β2-adrenergic agonist albuterol on parathyroid hormone-related protein signaling by pulmonary alveolar type II cells. Presented as a poster at Western Society for Pediatric Research 2007, Carmel, CA. [Abstract]

2006 XOPENEX (levalbuterol) Abstracts

1. Agrawal DK, Cheng G, Kelbe PW, Bakale R. Class-specific effect of the enantiomers of b2-agonists on the activation of nuclear factor kb in human airway smooth muscle cells (Abstract). Proceedings of the American Thoracic Society 2006;3:A77.

2. Agrawal DK, Kim MJ, Kelbe PW, Bakale R. Class-specificity of the binding of [3H](S)-albuterol in human airway smooth muscle cells (Abstract). Proceedings of the American Thoracic Society 2006;3:A467.

3. Agrawal DK, Cheng G, Kelbe P. Masking of corticosteroid-induced inhibition of NF-kb activation by (S)-albuterol in human airway smooth muscle cells and human blood lymphocytes (Abstract). JACI 2006, 117[2], S140.

4. Andrews T, McGintee E, Tyler L, Mittal M, Pawlowski NA, Zorc JJ. Safety of high-dose continuous levalbuterol (Abstract). JACI 2006, 117[2], S196.

5. Berger WE, Milgrom H, Kim K, Tripp K, Maier G, Baumgartner R. Levalbuterol HFA MDI for treatment of pediatric asthma: a double-blind, randomized, placebo- and active- controlled trial (Abstract). Annual Meeting of the Western Society of Allergy, Asthma, & Immunology. 2006.

6. Cheng G, Kelbe PW, Agrawal DK. Induction of nuclear factor kb activity and masking of the beneficial effect of corticosteroid by (s)-albuterol in human airway smooth muscle cells (Abstract). Proceedings of the American Thoracic Society 2006;3:A77.

7. Cleary JC, Karmazyn Y, Mogayzel PJ, Laube BL. Chronic administration of levalbuterol or racemic albuterol does not enhance mucociliary clearance in healthy subjects (Abstract). Proceedings of the American Thoracic Society 2006;3:A78.

8. Finn PW, Amirifeli S, He H, Campo M, Ferrada M, Barone L, Perkins D. Albuterol in an allergic murine model (Abstract). Proceedings of the American Thoracic Society 2006;3:A346.

9. Frieri M, Capetandes A. (R)-, but not (S)-, enantiomers of beta2 agonists inhibit IL-8 secretion by rsv antigen-stimulated confluent human alveolar epithelial cells (cA549) (Abstract). JACI 117[2], S318. 2006.

10. Mendes ES, Campos MA, Wanner A. A novel mechanism of glucocorticoid-adrenergic interaction in the regulation of airway blood flow (Abstract). Proceedings of the American Thoracic Society 2006;3:A688.

11. Milgrom H, Berger WE, Kim K, Tripp K, Maier G, Baumgartner R. Levalbuterol HFA MDI for treatment of pediatric asthma: a double-blind, randomized, placebo- and active- controlled trial (Abstract). Annual Meeting of Southwest Allergy Forum . 2006.

12. Morris GF, Johnson AR, Perry LA, Brody AR. Activation of the human proliferating cell nuclear antigen (PCNA) promoter in vivo and in cell culture by stereoisomers of albuterol (Abstract). Proceedings of the American Thoracic Society 2006;3:A697.

13. Puglisi G, Capetandes A, Frieri M. 10-6M (RR)-formoterol, but not (SS)-formotrol or (S)/(R)-albuterol, inhibits rantes secretion by rsv antigen- stimulated confluent human alveolar epithelial cells (cA549) (Abstract). JACI 117[2], S155. 2006.

14. Schulman ES, Nishi H, Pelleg A. Differential effects of albuterol stereoisomers on human lung mast cell mediator release (Abstract). Proceedings of the American Thoracic Society 2006;3:A589.

2005 XOPENEX (levalbuterol) Abstracts

1. Chorley BN, Adler KB. β2-adrenergic receptor activation with (r)-albuterol attenuates granulocyte macrophage colony stimulating factor (GM-CSF) expression via an iNOS-mediated pathway in human brochial epithelial cells in vitro. Proceedings of the American Thoracic Society 2005; 2:A757 (Abstract).

2. Codispoti C, Calhoun WJ, Ameredes BT. Eotaxin release from human airway smooth muscle cells treated with albuterol enantiomers. JACI 2005, 115(2):S48 (Abstract).

3. Donohue JF, Parsey M, Andrews C, D'Urzo T, Sharma S, Schaefer K, Claus R, Baumgartner R. Levalbuterol in the treatment of patients with Chronic Obstructive Pulmonary disease. CHEST 2005;128(4):260S. (Abstract).

4. Emerman C, Nowak R, Hanania N, Koester J, Claus R, Anderson A, Roach J, McVicar W, Hanrahan J. Fev1 response to levalbuterol vs racemic albuterol in acute severe asthma. Presented at the Aspen Allergy Conference, July 26 - 30, 2005, Aspen, CO (Abstract).

5. Frieri M, Capetandes A. (S)-albuterol increases CysLT1R expression and VEGF mRNA by normal human lung fibroblasts (NHLF). JACI 2005, 115(2):S14 (Abstract).

6. Frieri M, Capetandes A. Effect of (s)-albuterol vs (r)-albuterol on vascular endothelial growth factor, basic fibroblast growth factor and fibronectin secretion from normal human fibroblasts and myofibroblasts. Ann Allergy Asthma Immunol 2005; 1:185 (Abstract).

7. Hanania N, Emerman C, Nowak R, Claus R, Varga J, Andrews W, McVicar W, Hanrahan JP. FEV1 response to levalbuterol vs racemic albuterol in acute severe asthma. Presented at the Annual Meeting of the Southwestern Allergy Forum 2005, Puerta Vallarta, Mexico (Abstract).

8. Hanania N, Emerman C, Nowak R, Claus R, Snider ME, Varga J, Andrews W, McVicar W, Hanrahan JP. FEV1 response to levalbuterol vs racemic albuterol in acute severe asthma. Presented at the Annual Meeting of the Western Society of Allergy, Asthma, & Immunology 2005, Hawaii (Abstract).

9. Ozminkowski RJ, Long SR, Wang S, Barry N, Schaefer K. Healthcare utilization for elderly Medicaid patients treated with nebulized levalbuterol (LEV) or racemic albuterol (RAC). Proceedings of the American Thoracic Society 2005; 2:A925 (Abstract).

10. Perry A, Persinger R, Schwartz Y, Chang M, Wu R. (R)- and (S)-albuterol exhibit differential effects on mucociliary transport and mucin secretion. Presented at the Gordon Conference on Cilia, Mucus & Mucociliary Interactions, February 27 - March 4, 2005, Buellton, CA (Abstract).

11. Pikarsky RS, Acevedo RA, Farrell T, Fascia W. Breakthrough treatment rates during a conversion to levalbuterol, tiotropium and breath actuated nebulizers. CHEST 2005; 128(4):259S. (Abstract).

12. Pikarsky RS, Acevedo RA, Farrell T, Fascia W. Economic impact resulting from a conversion to levalbuterol every six to eight hours. CHEST 2005;128(4):259S. (Abstract).

13. Puglisi G, Horne N, Huang YC, Frieri M. Transforming growth factor beta 1 (TGF-β1) production and expression from ragweed stimulated human alveolar epithelial cells (A549): modulation by budesonide, formoterol, and levalbuterol. Ann Allergy Asthma Immunol 2005; 1:165 (Abstract).

14. Raissy HH, Harkins M, Esparham A, Kelly HW. A double-blind, placebo-controlled crossover comparison of the dose-response to levalbuterol for reversing methacholine-induced bronchoconstriction with and without pretreatment with (s)-albuterol. Proceedings of the American Thoracic Society 2005; 2:A356. (Abstract).

15. Rance K, Trent C. Improved asthma outcomes achieved through a synergistic relationship between education and pharmacology in a high-risk population. Presented at the National Association of Pediatric Nurse Practitioners Annual Meeting, March 31 - April 3, 2005, Phoenix, AZ (Poster).

2004 XOPENEX (levalbuterol) Abstracts

1. Agrawal DK, Kelbe PW. S-Albuterol Activates Pro-Constrictory and Inflammatory Pathways in Human Bronchial Smooth Muscle Cells. Am J Respir Crit Care Med 2004, 169:A860. (Abstract)

2. Agrawal DK, Kelbe PW. S-Albuterol Binds to Intracellular Organelles and Proteins in Human Airway Smooth Muscle Cells. Am J Respir Crit Care Med 2004, 169:A310. (Abstract)

3. Ameredes BT, Gligonic AL, Calhoun WJ. Enantiomers of beta-agonists exhibit differential effects in combination with dexamethasone on GM-CSF production in human airway smooth muscle cells. JACI 2004; 113(Suppl):S190 [Abstract].

4. Andrews W, Teicher MH, Polcari A, Pankratz M. Impact of racemic albuterol compared to leavaluterol on objective measures of hyperactivity and inattentiveness in children with asthma. J Allergy Clin Immunol. 2004;113(Suppl):S32. (Abstract)

5. Auais A, Wedde-Beer K, Piedimonte G. Dose-Response and Time Course of the Anti-Inflammatory Effect of Albuterol Isomers During Respiratory Syncytial Virus (RSV) Infection in Fisher-344 (F344) Rats. Am J Respir Crit Care Med 2004, 169:A757. (Abstract)

6. Banerjee A, McLaughlin NB, Hamiel C, Musters RJ, Kubista R, Silliman CC, Cairns CB. Attenuation of Inflammatory-Induced Oxidative Burst in Human Neutrophils By Albuterol is Enantiomer Specific. Am J Respir Crit Care Med 2004, 169:A802. (Abstract)

7. Calmes H, Ho CN, Digioia-Ross L. Assessment of the current use of levalbuterol inhalation solution in an academic teaching center: a retrospective chart review (Abstract). International Pharmaceutical Abstracts 2004;39:37e.

8. Chorley BN, Adler KB. Inducible Nitric Oxide Synthase/Protein Kinase G Signaling Pathway Suppresses Granulocyte Macrophage Colony Stimulating Factor Transcription in Normal Human Bronchial Epithelial Cells. Am J Respir Crit Care Med 2004, 169:A421. (Abstract)

9. Emerman C, Nowak R, Claus R, Roach J, Baumgartner RA, Hanrahan JP. Clinical Response to Levalbuterol (LEV) vs Racemic Albuterol (RAC) in Acute Asthma: Impact of (S)-Albuterol Levels. Am J Respir Crit Care Med 2004, 169:A310 (Abstract)

10. Garfinkel F. Adoption of levalbuterol at Hillcrest Medical Center: the effect on nebulized respiratory treatments. Respiratory Care 2004, Abstracts 2004 Open Forum p. 23 (Abstract)

11. Hanania N, Emerman C, Nowak R, Claus R, Roach J, McVicar W, Hanrahan J. FEV1 response to levalbuterol vs racemic albuterol in acute severe asthma. CHEST 2004; 126(4)Suppl:722S (Abstract)

12. Ibe B, Raj U. Effects of (R)- and (S)-Isomers of Albuterol on Human Airway Smooth Muscle (HASM) Proliferation. Am J Respir Crit Care Med 2004, 169:A871. (Abstract)

13. Lindberg L. Cost effectiveness of using levalbuterol vs racemic albuterol. Respiratory Care 2004, Abstracts 2004 Open Forum p. 22 (Abstract)

14. Nowak R, Emerman C, Claus R, Schaefer K, McVicar W, Hanrahan JP, Baumgartner RA. Levalbuterol (LEV) vs Racemic Albuterol (RAC) in Acute Severe Asthma: A Prospective Trial. Am J Respir Crit Care Med 2004, 169:A310. (Abstract)

15. Nowak R, Emerman C, Silverman R, Baumgartner R, Hanrahan JP. Impact of blood levels of (S)- albuterol (S-AL) on response to levalbuterol (LEV) and racemic albuterol (RAC) in the emergency department. Acad Emerg Med 2004;11:556. [Abstract]

16. Oh CK, Abraha D, Agrawal DK, Park JM, Cho SH. (S,S)-formoterol increases the production of IL-4 in mast cells and the airways of a murine asthma model. JACI 2004; 113(Suppl):S32 [Abstract].

17. Okabe-Yamamura T, Leong S. Impact of an automatic dosing interchange for levalbuterol (Abstract). Int Pharm Abs 2004;39:70D.

18. O'Riordan TG, Palmer LB. Quantifying effects of albuterol on airway secretions in ventilator associated tracheo-bronchitis. Am J Respir Crit Care Med 2004, 169:A125. (Abstract)

19. Otte R, Gentile D, Angelini B, Krahnke J, Richards H, Trecki J, Doyle W, Skoner D. Effect of levalbuterol on exhaled nitric oxice (NO) levels in asthmatic subjects. J Allergy Clin Immunol. 2004;113(Suppl):S32-S33. (Abstract)

20. Qureshi F, Zaritsky A, Welch C, Meadows T. Clinical efficacy of racemic albuterol versus levalbuterol for the treatment of acute pediatric asthma. Pediatric Research 2004; 55:115A (Abstract).

21. Thomas JA, Petty M. Evaluation of patient outcomes associated with nebulized levalbuterol and racemic albuterol in patients hospitalized with COPD or asthma using six sigma methodology (Abstract). International Pharmaceutical Abstracts 2004;39:60e.

22. van Zale S, Bakos S. From levalbuterol to albuterol: implmentation of an innovative therapeutic interchange in a community hospital (Abstract). International Pharmaceutical Abstracts 2004;39:66d.

23. Wachi S, Chuang CY, Chang MMJ, Snider ME, Wu R. Profiling gene expression patterns in airway epithelial cells treated with albuterol isomers. Am J Respir Crit Care Med 2004, 169:A55. (Abstract)

2003 XOPENEX (levalbuterol) Abstracts

1. Ameredes BT, Gilgonic CM, Neely C, Robinson WJ, Calhoun WJ. Low-dose Enantiomeric Beta-agonists Modulate IL-6 Production in Human Airway Smooth Muscle Cells. J Allergy Clin Immunol. 2003;111:A539. Abstract.

2. Berger W.E., Ames D. A patient satisfaction survey comparing levalbuterol to racemic albuterol in children (abstract). Journal of Allergy and Clinical Immunology 2003;111(2 Suppl.):S214.

3. Carl JC, Myers TR, Kirchner HL, Kercsmar CM. Racemic albuterol is less effective than levalbuterol for treatment of acute asthma in children (Abstract). J Peds 2003

4. Colice G, Carnathan B, Paramore LC, Sendersky V, Sung J, Gause D. Economic evaluation of inpatient bronchodilator therapies. Ann. Allergy Asthma Immunol. 2003;90(1):127. (Abstract)

5. Giri VV, Dhand R, Depinto DJ, Mason GR, Gross NJ, Reyes C, Kelbe P, Koch P. (S)- and (R)- enantiomer levels in resected lung specimens after regular inhalation of racemic albuterol. Am J Respir Crit Care Med. 2003;165;A185. (Abstract).

6. Johnson JL, Gibson CD, Cox JF. Conversion from racemic albuterol to levalbuterol. Int Pharm Abs 2003;38:P-12. [Abstract]

7. LeNoir M, Nguyen M, Vaickus L., Shcaefer K. Efficacy of Levalbuterol in African American Patients with Asthma. Ann. Allergy Asthma Immunol. 2003; 90(1):126. (Abstract).

8. Lieu PA, Albin C, Barraza P, Li P. Levalbuterol provides cost savings over racemic albuterol in the treatment of acute asthma in hospitalized pediatric patients. International Pharmaceutical Abstracts 2003; 38:P155. (Abstract)

9. Pikarsky RS, Acevedo RA, Farrell T, Bear R, Fascia W. Comparison in rates of breakthrough treatments during a conversion from racemic albuterol to levalbuterol (Abstract). Respiratory Care 2003;48(11):1080.

10. Pleskow W, Nelson H, Schaefer K, Claus R, Roach JM. Levalbuterol (LEV) shows enhanced clinical benefit over racemic albuterol (RAC) (Abstract). Annals of Allergy, Asthma, & Immunology 2003;92(1):111-112.

11. Reyes N, Vorasubin N, Thach TT, Kwong CC, Robert RL. The effects of albuterol and levalbuterol on the activation of leukocytes by CD64+ and CD69+ expression (Abstract). FASEB Journal 2003 March 11;17(4-5).

12. Schreck DM, Babin S. Pharmacoeconomic comparison of albuterol and levalbuterol in the treatment of acute asthma (Abstract). Critical Care Medicine 2003;31:PA66.

13. Skoner D.P., Kim K.T., Greos L.S. Levalbuterol in 2-5 Year Old Children with Asthma: Results of a Large Clinical Trial.Ann Allergy Asthma Immunol. 2003; 90(1):127. (Abstract)

2002 XOPENEX (levalbuterol) Abstracts

1. Agrawal DK. Detrimental effect of (SS)-formoterol and (S)-albuterol is due to an increase in Gi-a1 and Gi-a3 proteins and activation of NF-kB in human airway smooth muscle cells. Am J Respir Crit Care Med. 2002;165:A317. Abstract.

2. Ameredes BT, Neely C, Calhoun WJ. Il-6 production by human airway smooth muscle cells treated with (R)- and (S)-enantiomers of Beta-Agonists. Am J Respir Crit Care Med. 2002;165:A312. Abstract.

3. Calhoun W, Ameredes B, Neely C, Dixon-McCarthy B. Production of IL-10 relative to TNF-alpha by blood mononuclear cells is enhanced by R-enantiomers of beta-receptor agonists. JACI 2002;109:S21. Abstract.

4. Canning B. Pharmacological properties of (S)-albuterol (ALB) in human airway smooth muscles (HASM) preparations. Am J Respir Crit Care Med. 2002;165;A770. Abstract.

4. Colice G, Vaickus L. Second hand (S)- albuterol: RT exposure risk after racemic albuterol. Annals of Allergy, Asthma, & Immunol 2002;88:132. (Abstract)

5. Grogan D, Schaefer K, Claus R. Levalbuterol improves asthma and COPD symptoms with fewer side effects. J Allergy Clin Immunol. 2002;109:S719. (Abstract)

6. Maier G, Henry A, Baumgartner R, Rubino C, Cirincione B, Grasela T. The Effect of the distomer, (S)- albuterol, is not through alteration of the pharmacokinetics of (R)- albuterol: A population PK analysis. J Allergy Clin Immunol. 2002;109:S719. Abstract.

7. Ohar J, Grogan D, Schaefer K. Physicians and patients prefer levalbuterol to racemic albuterol [abstract]. Annals of Allergy, Asthma, & Immunology 2002;88:132.

8. Pereira A, Mendes E, Wanner A. Effect of Inhaled racemic and (R)-albuterol on airway vascular smooth muscle in healthy and asthmatic subjects. Am J Respir Crit Care Med. 2002;165;A717. Abstract.

9. Pikarsky RS, Acevedo RA. Clinical and economic impact resulting from a hospital-wide conversion from racemic albuterol to levalbuterol. CHEST 2002;122:146S. (Abstract)

10. Pikarsky RS, Acevedo RA, Roman C, Farrell T. Comparison in rates of breakthrough treatments during a conversion from racemic albuterol to levalbuterol. CHEST 2002;122:25S. (Abstract)

11. Schwartz Y, Tarantino P, Jerussi T. (R)- and (S)-albuterol exhibit differential effects on mucociliary transport velocity. CHEST 2002;122: Abstract.

12. Vaickus L, Schaefer K, Claus R. Impact of decreasing doses of racemic albuterol and levalbuterol on efficacy: A pooled analysis. J Allergy Clin Immunol. 2002;109:S707. (Abstract)